Viridian Therapeutics Inc (NAS:VRDN)
$ 11.95 0.01 (0.08%) Market Cap: 762.68 Mil Enterprise Value: 369.62 Mil PE Ratio: 0 PB Ratio: 1.99 GF Score: 44/100

Q2 2019 miRagen Therapeutics Inc Earnings Call Transcript

Aug 07, 2019 / 08:30PM GMT
Release Date Price: $23.55 (+18.05%)
Operator

Greetings and welcome to miRagen Therapeutics Q2 2019 Earnings Conference Call. (Operator Instructions) Please note, this conference is being recorded.

I would now like to turn the conference over to your host, Mr. Dan Ferry. Thank you. You may begin.

Daniel Ferry
LifeSci Advisors, LLC - MD & Relationship Manager

Thank you, and good afternoon, everyone. On the call today are miRagen's President and Chief Executive Officer, Bill Marshall; Chief Financial Officer, Jason Leverone; and Executive Vice President of Research & Development, Paul Rubin.

Before we begin, I would like to remind everybody that this conference call and webcast will contain forward-looking statements about the company. These statements are subject to risks and uncertainties that could cause actual results to differ. Please note that these forward-looking statements reflect our opinions only as of the date of this call. We will not undertake an obligation to revise or publicly release the results of any revisions to these forward-looking statements in the light of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot